Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comparing HMG-CoA reductase inhibitors.

Peter H Jones1

  • 1Baylor College of Medicine, Houston, Texas 77030, USA. jones@bcm.tmc.edu

Clinical Cardiology
|January 24, 2003
PubMed
Summary

Statins effectively lower low-density lipoprotein (LDL) cholesterol, reducing coronary heart disease (CHD) risk and proving well-tolerated. Further research is exploring their benefits beyond lipid reduction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Journal of clinical lipidology·2022
Same author

Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).

Journal of clinical lipidology·2021
Same author

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies.

Cardiology and therapy·2020
Same author

Authors' response to letter by Anagnostis and Stevenson, "Is there a role for menopausal hormone therapy in a woman with increased lipoprotein(a) concentrations?"

Journal of clinical lipidology·2020
Same author

"Zero": The New Superhero or Superhero in Training?

Journal of the American College of Cardiology·2019
Same author

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Journal of clinical lipidology·2019

Area of Science:

  • Cardiovascular Pharmacology
  • Medicinal Chemistry

Background:

  • Statins are primary therapies for lowering low-density lipoprotein (LDL) cholesterol and reducing coronary heart disease (CHD) risk.
  • Individual statin characteristics (chemical derivation, solubility, metabolism) may influence tolerability and efficacy, though explanations for differential LDL reduction remain unclear.

Purpose of the Study:

  • To review the clinical relevance of individual statin drug characteristics.
  • To explore the reasons for varying LDL cholesterol reductions among different statins.
  • To investigate the effects of statins on high-density lipoprotein (HDL) and potential non-lipid benefits.

Main Methods:

  • Literature review of clinical trials and pharmacological studies on statins.
  • Comparative analysis of LDL cholesterol reduction across various statin agents.
  • Exploration of proposed mechanisms for differential efficacy and pleiotropic effects.

Main Results:

  • Several statins demonstrate significant CHD risk reduction and good tolerability in primary and secondary prevention.
  • Differential LDL cholesterol lowering effects among statins (e.g., atorvastatin, rosuvastatin) are observed but not fully explained.
  • Emerging evidence suggests statins may have beneficial effects beyond lipid modification.

Conclusions:

  • Statins are effective and well-tolerated therapies for managing hyperlipidemia and reducing cardiovascular risk.
  • Further research is needed to elucidate the clinical significance of specific statin properties and their non-lipid-lowering effects.

Related Experiment Videos